Condition: Ultomiris-exposed Pregnant/ Postpartum · Pregnancy · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Melbourne, Victoria, Australia | Not Yet Recruiting |
| Research Site | Paris, France | Recruiting |
| Research Site | Essen, Norte-Westfalia, Germany | Recruiting |
| Research Site | Rome, Italy | Recruiting |
| Research Site | Seoul, South Korea | Active Not Recruiting |
| Research Site | London, United Kingdom | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06312644